Table 1 Mutual exclusivity analysis of the inhibitory immune checkpoints in pancreatic cancer
From: Identification of CEACAM5 as a stemness-related inhibitory immune checkpoint in pancreatic cancer
A | B | Neither | A Not B | B Not A | Both | Log2 Odds Ratio | p-Value | q-Value | Tendency |
|---|---|---|---|---|---|---|---|---|---|
BTN2A2 | BTNL2 | 144 | 0 | 3 | 2 |  > 3 |  < 0.001 | 0.046 | Co-occurrence |
CD274 | PDCD1LG2 | 146 | 1 | 0 | 2 |  > 3 |  < 0.001 | 0.03 | Co-occurrence |
CD274 | FGL1 | 145 | 1 | 1 | 2 |  > 3 |  < 0.001 | 0.046 | Co-occurrence |
CD276 | BTNL9 | 145 | 1 | 1 | 2 |  > 3 |  < 0.001 | 0.046 | Co-occurrence |
CD80 | CD86 | 144 | 0 | 3 | 2 |  > 3 |  < 0.001 | 0.046 | Co-occurrence |
CEACAM5 | CD86 | 142 | 2 | 2 | 3 |  > 3 |  < 0.001 | 0.03 | Co-occurrence |
CEACAM5 | AXL | 140 | 2 | 4 | 3 |  > 3 |  < 0.001 | 0.046 | Co-occurrence |
CEACAM5 | CD80 | 144 | 3 | 0 | 2 |  > 3 |  < 0.001 | 0.046 | Co-occurrence |
IDO1 | IDO2 | 143 | 1 | 1 | 4 |  > 3 |  < 0.001 |  < 0.001 | Co-occurrence |
NECTIN2 | PVR | 144 | 1 | 0 | 4 |  > 3 |  < 0.001 |  < 0.001 | Co-occurrence |
NECTIN2 | AXL | 141 | 1 | 3 | 4 |  > 3 |  < 0.001 | 0.002 | Co-occurrence |
PVR | AXL | 141 | 1 | 4 | 3 |  > 3 |  < 0.001 | 0.03 | Co-occurrence |
VTCN1 | CD80 | 145 | 2 | 0 | 2 |  > 3 |  < 0.001 | 0.046 | Co-occurrence |